Press Releases


January 9, 2020

Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference



December 9, 2019
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development

November 18, 2019
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program

September 23, 2019
FierceBiotech: Nkarta Therapeutics recognized as 2019 Fierce 15 company.

September 18, 2019
Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer

September 9, 2019
Nkarta Therapeutics Appoints Vice President of Regulatory Affairs

September 4, 2019
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trial

April 1, 2019
Nkarta Therapeutics Presents Data at Aacr Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity Of NK Cells



December 10, 2018
Nkarta Therapeutics announces appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer

November 27, 2018
Nkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer

November 9, 2018
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity In Preclinical Tumor Model

July 9, 2018
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters

June 11, 2018
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology from National University of Singapore and St. Jude Children’s Research Hospital

March 1, 2018
Nkarta Therapeutics Appoints Veteran Executive Paul Hastings As CEO To Lead Next Phase Of Growth